The Action Collaborative on Preventing Sexual Harassment in Higher Education—part of the National Academies of Science, Engineering, and Medicine—published its first collaborative resource: a Guidance Document on Measuring Sexual Harassment Prevalence Using Campus Climate Surveys.
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) showed that chronic physiologic “wear and tear” from stress, known as allostatic load, may be associated with a decreased likelihood of cancer treatment completion and lower overall survival.
Researchers at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and the Mayo Clinic have discovered a way to supercharge molecular cancer treatments to destroy more cancer-causing proteins in cells.
The Lung Cancer Master Protocol public-private partnership—which includes the NCI, the National Clinical Trials Network Cooperative Groups (SWOG, ECOG-ACRIN, Alliance, and NRG), Friends of Cancer Research, and the Foundation for the National Institutes of Health—will study the IL-15 receptor superagonist complex Anktiva (N-803) in the Lung-MAP clinical trial.
According to researchers from the University of North Carolina Lineberger Comprehensive Cancer Center, pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma improved the immunotherapy’s effectiveness.
NRG Oncology activated FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps, or NRG-CC005), a large, randomized trial of surveillance colonoscopy for participants with a first-time diagnosis of 1 or 2 adenomas.
A study identified racial and ethnic disparities in survival among newly diagnosed patients with childhood cancers in the U.S., with area-level socioeconomic status and health insurance contributing to these disparities.
Scientists at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute of The Ohio State University Comprehensive Cancer Center are studying tissues collected within hours of death to gather clues as to why certain cancers are able to spread and evolve.
Researchers at City of Hope showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects when a multidisciplinary team of experts analyzed each case and introduced personalized interventions.
According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
